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The complement system is a tightly regulated network of proteins involved in defense
against pathogens, inflammatory processes, and coordination of the innate and adaptive
immune responses. Dysregulation of the complement cascade is associated with many
inflammatory disorders. Thus, inhibition of the complement system has emerged as an
option for treatment of a range of different inflammatory diseases. MAP-1 is a pattern
recognition molecule (PRM)-associated inhibitor of the lectin pathway of the complement
system, whereas C4b-binding protein (C4BP) regulates both the classical and lectin
pathways. In this study we generated chimeric proteins consisting of MAP-1 and the first
five domains of human C4BP (C4BP1−5) in order to develop a targeted inhibitor acting
at different levels of the complement cascade. Two different constructs were designed
and expressed in CHO cells where MAP-1 was fused with C4BP1−5 in either the C- or
N-terminus. The functionality of the chimeric proteins was assessed using different in
vitro complement activation assays. Both chimeric proteins displayed the characteristic
Ca2+-dependent dimerization and binding to PRMs of native MAP-1, as well as the
co-factor activity of native C4BP. In ELISA-based complement activation assays they
could effectively inhibit the lectin and classical pathways. Notably, MAP-1:C4BP1−5
was five times more effective than rMAP-1 and rC4BP1−5 applied at the same time,
emphasizing the advantage of a single inhibitor containing both functional domains. The
MAP-1/C4BP chimeras exert unique complement inhibitory properties and represent a
novel therapeutic approach targeting both upstream and central complement activation.
Keywords: complement activation, lectin pathway, classical pathway, MAP-1, C4BP, complement inhibition,
chimeric protein
INTRODUCTION
The complement system constitutes a central effector arm of the vertebrate immune system
occupying a pivotal position as an early danger sensor and mediator of immunological and
inflammatory processes (1, 2). Complement is activated via three distinct pathways, i.e., the
classical (CP) the lectin (LP) and the alternative pathway (AP) that converge on the generation
and deposition of opsonins, release of anaphylatoxins, and generation of the terminal complement
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complex (TCC) which all together help coordinating the cellular
and humoral immune responses (3–6).
Initiation of CP is mediated mainly by the binding of C1q
to immune-complexes, but also to conserved pathogen-specific
structures, altered self-antigens or interaction with the pentraxins
(7) and leads to the activation of the serine proteases C1r
and C1s (8, 9). The LP is initiated by two groups of pattern
recognition molecules (PRM): c-type lectins, such as mannose-
binding lectin (MBL), collectin-10 (CL-10, CL-L1), and collectin-
11 (CL-11, CL-K1) and ficolins, i.e., ficolin-1 (M-ficolin), ficolin-
2 (L-ficolin), and ficolin-3 (H-ficolin or Hakata antigen). Binding
of PRMs to ligands activates the MBL-associated serine proteases
(MASPs), causing cleavage and activation of C2 and C4 (10). The
AP is constantly “probing” surfaces in a non-specific fashion by
means of a constitutive low level of spontaneous hydrolysis of
C3 into the C3b analog C3(H2O) (11). Maybe more importantly,
C3b generated from any of the three pathways is amplified
via the AP. In fact, AP amplification may account for up to
90% of the total complement activation independently of the
triggering pathway (7, 12). Whether the AP can be activated
via a similar PRM-dependent mechanism involving properdin
remains controversial (13, 14).
Complement is much more than a pathogen-sensing
system, with ties spanning into coagulation, inflammation and
embryonic development (2). In order to carry out its diverse
functions it relies on a delicate balance between activation and
inhibition by means of a set of membrane-bound and soluble
regulatory proteins (15), the latter including the LP inhibitor
MBL/ficolin/CL-associated protein 1 (MAP-1, also named
MAp44), and the LP and CP regulators C4b-binding protein
(C4BP) and C1 inhibitor (a protease inhibitor of the serpin super
family that inactivates C1r, C1s, MASP-1, and MASP-2) (16).
Two genes encode all five naturally-occurring MASP isoforms
in mammals (17): three proenzymes (i.e., MASP-1, -2, and
-3) and the two non-proteolytic proteins sMAP (MAp19) and
MAP-1. The proteolytic MASPs consist of a heavy chain—
comprised of two CUB domains separated by an epidermal
growth factor (EGF) domain, and two complement control
protein/short consensus repeats (CCP/SCR) modules—and a
light chain composed of the serine protease domain. MAP-1
differs from the proteolyticMASPs in that it lacks the second SCR
and SP domain and thus it cannot activate complement. MAP-1
competes with the MASPs in binding to recognition molecules of
the LP leading to decreased complement activation. This has been
demonstrated in vitro (18–20), and in multiple in vivo disease
models (21, 22).
C4BP is a soluble protein encoded in the regulator of
complement activation (RCA) gene locus of chromosome 1
(23) and possesses a unique structure among the RCA proteins
in being a polymer composed of several CCP containing
polypeptides. The most abundant isoform in the circulation
is composed of seven identical α-chains (75 kDa each) and
Abbreviations: CP, LP, AP, Classical, lectin, and alternative pathway; PRM,
Pattern recognition molecule; IC50, Half maximal inhibitory concentration; Kd,
half maximal binding concentration; SEM, Standard error of the mean; PTEC,
Proximal tubular epithelial cells.
one β-chain (45 kDa) linked together by a central core and
found in a high affinity complex with the anticoagulant vitamin
K-dependent protein S (24, 25). The complement regulatory
functions of C4BP are located within the first CCP domains of
the α-chains. C4BP binds to the negatively-charged surface of
C4b via the first three CCP domains of the α-chain preventing
the assembly of the classical and lectin pathways C3 convertases
(26, 27). Additionally, C4BP acts as a cofactor in the complement
factor I (fI)-mediated proteolytic inactivation of both soluble
and membrane bound C4b (28–30). By binding to C3b via the
first 4 CCP domains of the α-chain, C4BP also participates in
the fI-dependent C3b degradation to iC3b in the fluid phase
(31). Although it is difficult to speculate upon the genuine
physiological role of the inhibitory function of C4BP since no
C4BP deficiency has been diagnosed in humans (32), C4BP
injected peritoneally has been shown to alleviate inflammation
and tissue damage in collagen- and collagen antibody-induced
arthritis mouse models (33).
Since the US Food and Drug Administration approval of the
first complement-specific drug in 2007 (34), rational modulation
of the complement cascade using complement inhibitors has
gradually demonstrated its potential as a drug discovery strategy
and therapeutic treatment (35). Especially recombinant chimeric
proteins targeting different levels of the cascade are of great
interest in complement-mediated therapy and have previously
been created with success (36, 37). Here we aimed to create a
dual inhibitor with the ability to target initial activation by both
the lectin and classical pathways by combining full length MAP-
1 with the first five N-terminal CCP domains of the α-chain of
C4BP. This could provide a unique platform for a novel class of
complement inhibitor and thus contribute to the emerging field
of complement therapeutics.
MATERIALS AND METHODS
Buffers
The following buffers were used: PBS (0.2M Na2HPO4,
35mM K2HPO4, 0.15M NaCl, 15mM KCl), PBS/NaCl
(0.2M Na2HPO4, 35mM K2HPO4, 0.5M NaCl, 15mM KCl),
TBS/Ca2+ and TBS/Tw/Ca2+ (20mM Tris-HCl, 150mM NaCl,
5mM CaCl2, with/without 0.05% Tween-20), TBS/EDTA and
TBS/Tw/EDTA (20mM Tris-HCl, 150mM NaCl, 10mM EDTA,
with/without 0.05% Tween), VBS/Tw and sample buffer (4mM
C8H11N2NaO3, 145mM NaCl, 2.6mM CaCl2, 2mM MgCl2,
with 0.05% Tween-20 or 0.5% BSA respectively).
Design of Chimeric Proteins and
Transfection
The coding sequences for MAP-1 (NM_001031849.2) and C4BP
(NM_000715.3) were optimized for expression in Chinese
hamster ovarian (CHO) cells in terms of codon adaptation index,
mRNA stability, GC content, removal of cryptic splice sites, and
repeats, 5’ UTR, and signal peptide. All DNA manipulations
were performed in Visual Gene Developer (38). MAP-1:C4BP1−5
comprises the coding sequence of MAP-1 followed by the first
five CCP domains of the α-chain of C4BP (C4BP1−5). The
reverse construct C4BP1−5:MAP-1 was designed with the coding
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sequence of C4BP1−5 located in the N-terminus of MAP-1 and
separated by a flexible glycine serine linker (G4S)3. A control
construct consisting of C4BP1−5 alone was designed with a C-
terminal hexa histidine-tag. In all cases, the signal peptide of
MAP-1 was used to ensure secretion. The chimeric constructs
were cloned into the pcDNA5/FRT vector and transfected
into Flp-in CHO cells (both from Invitrogen, Thermo Fisher
Scientific, USA) according to the manufacturer’s instructions.
Positive transfectants were selected for Hygromycin resistance
in complete medium with Ham’s F-12 Nutrient Mix, 10%
fetal calf serum, 2mM L-Glutamine, 1% Penicillin-Streptomycin
(Sigma-Aldrich, USA), and 500mM of Hygromycin B (all from
Gibco, Thermo Fisher Scientific unless otherwise stated), and
maintained at 37◦C in a humidified atmosphere with 5% CO2.
Purification of Recombinant Proteins
The chimeric constructs were purified by immunoaffinity
chromatography using the monoclonal antibody (mAb) anti-
MAP-1 20C4 (39) coupled to cyanogen bromide-activated-
sepharose 4B (Sigma-Aldrich). Briefly, filtered cell culture
supernatants were applied to the column and washed in
PBS/NaCl. Bound protein was eluted with 0.5% (w/v) citric
acid (pH 2.5) and neutralized with 1M Tris-HCl (pH 9).
Elution fractions were applied on a NuPAGE bis-tris 4–12%
polyacrylamide gel (Invitrogen), followed by a direct protein
stain with Instant Blue (Expedeon LTD, UK) to assess the purity.
The concentration of the chimeric proteins was interpolated by
ELISA using rMAP-1 as standard. rC4BP1−5 was purified with a
HisTrap excel column (GE Healthcare, Denmark) according to
the manufacturer’s instructions.
SDS-Page and Western Immunoblotting
SDS-PAGE was performed using NuPAGE bis-tris 4–12% gels
with or without reducing agent and blotted onto HybondTM-
ECL nitrocellulose membranes (GE Healthcare) according to
the manufacter’s instructions. The membranes were probed with
0.5µg/ml anti-MAP-1 20C4 or 0.3µg/ml anti-human C4BP
polyclonal antibody (pAb; Abnova, 722-D01P, Taiwan) overnight,
followed by 1 h incubation with 0.4µg/ml rabbit anti-mouse-
HRP pAb (Dako, P0260, Denmark) or a 1:4000 dilution of
donkey anti-rabbit-HRP pAb (GE Healthcare, NA934V) for
MAP-1 and C4BP, respectively. The membranes were developed
with SuperSignal WestFemto (Thermo Fisher Scientific) and
analyzed with Microchemi (Bio-imaging systems, Israel).
Fluid Phase C4BP Cofactor Assay
The cofactor activity of C4BP, MAP-1:C4BP1−5, and
C4BP1−5:MAP-1 was assessed with an established fluid
phase cofactor activity assay (40, 41) measuring the fI-cofactor
activity of C4BP in the proteolytic inactivation of C4b and
C3b. Briefly, C4b and C3b were incubated with fI, complement
factor H (fH), and equimolar concentrations of full length C4BP
(all from Complement Technology Inc., USA), recombinant
MAP-1 (rMAP-1, produced in house), MAP-1:C4BP1−5, or
C4BP1−5:MAP-1 for 2 h at 37◦C. The reactions were stopped
with LDS sample buffer and reducing agent (both from
Invitrogen). Samples were subjected to electrophoresis and
immunoblotting as described above. Cleavage of C3b was
visualized by incubation with 1.6µg/ml rabbit anti-human C3d
pAb (Dako, A006302) followed by donkey anti rabbit-HRP
(GE Healthcare, NA934V) in a 1:5000 dilution. C4b cleavage
was assessed by incubation with 0.3µg/ml mouse anti-human
C4d mAb (Thermo Fischer Scientific) and 0.4µg/ml rabbit anti
mouse-HRP (Dako). Membranes were developed as described
previously.
Size Exclusion Chromatography (SEC)
The chimeric proteins (50 µg) were applied to a Superdex 200
HR 10/30 column (GE Healthcare) with a flow rate of 0.5 ml/min
in TBS/Ca2+ or TBS/EDTA. The eluate was collected in 1ml
fractions and analyzed by ELISA (see below).
ELISA
Assessment of Ca2+-Dependent Dimerization by
Sandwich ELISA Following SEC
Microtiter wells (MaxiSorp plate; Thermo Fisher Scientific) were
coated with anti-C4BP pAb (2µg/ml) in PBS overnight at 4◦C.
SEC fractions were applied in a two-fold dilution starting at
1:20 and incubated for 2 h. Biotinylated 8B3 mAb (2µg/ml),
recognizing the common heavy chain of MASP-1, MASP-3 and
MAP-1 (39), was used as detection antibody for 2 h. Streptavidin-
HRP conjugate (Sigma Aldrich, RPN1231V) (1:2000) was added
for 1 h and the plates were developed with substrate solution
TMB One (Kem Em Tek, Denmark). The reaction was stopped
with 0.2M H2SO4 and the absorbance was measured at 450 nm
using an ELx80 absorbance reader (BioTek, USA).
Binding of Chimeric Proteins to Ligand-Bound MBL
and CL-11
Microtiter wells were coated with 10 µg/ml mannan (Sigma
Aldrich) in PBS overnight at 4◦C followed by incubation
with recombinant MBL or recombinant CL-11 (rMBL and
rCL-11 produced in house; 2µg/ml) (42). Serial dilutions of
MAP-1:C4BP1−5, C4BP1−5:MAP-1, rMAP-1, and rC4BP1−5 in
TBS/Tween/Ca2+ or TBS/Tween/EDTA starting at 13.5 nM
were allowed to complex with rMBL for 2 h. Detection and
development were done as described above. Binding of rMBL
and rCL-11 to mannan was confirmed using biotinylated anti-
MBL Hyb-131-1 mAb and anti-CL-11 Hyb-15 mAb (2µg/ml),
respectively.
Complement Activation Assays
Inhibition of complement activation via the LP was determined
by an established ELISA-based assay (42) using specific
antibodies to detect the activated and deposited products of
C4, C3, and TCC. The chimeric proteins ability to inhibit
complement was tested in MBL defect serum (43) and normal
human serum (NHS). Mannan (10µg/ml) was immobilized onto
microtiter plates and incubated in PBS overnight at 4◦C followed
by incubation with 2µg/ml rMBL for 1.5 h. Serial dilutions
of rMAP-1, C4BP1−5:MAP-1, and MAP-1:C4BP1−5 starting at
667 nM were incubated with mannan/rMBL complexes for 1 h
prior to addition of 2% MBL defect serum. When using NHS as
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a complement source, serial dilutions of C4BP1−5:MAP-1, MAP-
1:C4BP1−5, MAP-1, and purified C4BP, starting at 667 nM, were
added to round bottom non-absorbent titration plates (Thermo
Fisher Scientific) with 2% NHS. The serum-protein mix was
incubated 30min at 4◦C, transferred to mannan (10µg/ml)
coated plates and incubated for 45min at 37◦C. Detection of
deposition fragments was quantified with 2µg/ml biotinylated
mouse mAbs anti-human C4 (Anti-C4) (Bioporto Diagnostics,
Denmark, Hyb 162-02), 2µg/ml anti-human C3bc BH6 (44),
and 1µg/ml anti-human C5b-9 (anti-TCC; Bioporto, Dia 011–
01) incubated for 2 h. Finally, Streptavidin-HRP conjugate was
added in a 1:2000 dilution for 1 h. Unless otherwise specified,
all washes and incubation steps were done with VBS/Tw.
Development was performed with substrate solution TMB
One. Data are represented as inhibition (%), calculated as
[(ODinhibitor –ODbackground)/(ODnoinhibitor –ODbackground)]100.
Total Complement Screen
The WieslabTM Complement System Screenkit COMPL 300
(Euro diagnostica, Sweden) (45), a standardized immunoassay
for measuring TCC formation by all three complement pathways,
was used to assess the inhibitory capabilities of the chimeric
proteins beyond the LP. MAP-1:C4BP1−5, C4BP1−5:MAP-1,
rMAP-1, rC4BP1−5, and rMAP-1 plus rC4BP1−5 (starting at
667 nM for LP and CP, and at 2667 nM for AP) were applied
in a two-fold dilution in non-absorbent titration plates in the
respective buffers for each pathway provided with the kit. NHS in
a 1:100 dilution for the CP and LP and a 1:20 for the AP was co-
incubated with the inhibitors for 30min at 4◦C. Protein/serum
mixes were transferred to pre-coated 96-well microtiter plates
and incubated 1 h at 37◦C. Following incubation the samples
were analyzed with the Wieslab Complement System Screenkit
according to the instruction from the manufacturer. Data are
represented as described in the previous paragraph without
background subtraction.
Flow Cytometry
Complement activation on kidney cells was studied by flow
cytometry using HK-2 cells (ATCC, CRL-2190), an immortalized
human proximal tubular epithelial cell (PTEC) line reported to
be a suitable alternative to freshly isolated PTCs (46). Cells were
cultured in Keratinocyte Serum Free Medium supplemented
with bovine pituitary extract, human recombinant epidermal
growth factor (all from Gibco) and 0.5% Penicillin-Streptomycin
(Sigma-Aldrich). On the day of the experiments, the cells
were detached with TryPLE Express Enzyme, washed with pre-
warmed Hank’s balanced salt solution (both from Gibco) with
calcium and magnesium, and transferred to polystyrene round
bottom tubes (Corning, USA). Data was collected using a Gallios
flow cytometer and analyzed by the Kaluza software 1.2 (both
from Beckman Coulter, USA). Values are reported as median
fluorescence intensities (MFI). To ensure analysis of single cells,
a forward scatter area vs. height gate was defined upon a
uniform gated population on the forward vs. side scatter (see
Supplementary Figure 1). A total of 10,000 events were recorded
per experimental condition.
Binding of MBL to Kidney Cells
HK-2 cells (1.0 × 105 cells/test) were incubated with serial
dilutions of rMBL for 30min at 4◦C in sample buffer with or
without EDTA. Prior to the addition of the detection antibody,
the cells were fixed in a 1% solution of paraformaldehyde (Sigma
Aldrich) for 10min. Bound rMBLwas detected using anti-human
MBLHyb 131-11mAb (2µg/ml) for 30min plus goat anti-mouse
PE conjugate (Sigma, P9670) in a 1:20 dilution for 20min in the
dark. The cells were washed with sample buffer at 300 × g for
5min in between steps and all manipulations were performed at
4◦C.
Complement Deposition on Kidney Cells
HK-2 cells (1.0 × 105 cells/test) were incubated with rMBL
for 30min, followed by 10% MBL defect serum for 1 h. The
cells were fixed with 1% paraformaldehyde for 10min. Surface-
bound C4 was measured with biotinylated anti-human C4c pAb
(2µg/ml) (Dako, Q036905) for 30min followed by Streptavidin
APC conjugate (1:400) (Invitrogen, SA1005) for 20min in
the dark. To study the impact of the chimeric inhibitors
on C4 deposition, serial dilutions of MAP-1:C4BP1−5, and
C4BP1−5:MAP-1, rMAP-1, and C4BP1−5 (200 nM) were allowed
to react with 10% MBL defect serum for 20min prior to
incubating with the rMBL-bound HK-2 cells for 1 h. After fixing
the cells C4 deposition was measured as described previously. All
washes and incubation steps were done in sample buffer at 4◦C.
Statistics
All statistical analyses were performed in GraphPad Prism
software 7.02 (GraphPad, USA). Kd values (i.e., ligand
concentration required to achieve half of the maximum
binding) were calculated using the equation specific binding with
Hill slope after subtracting the background OD and constraining
the Bmax (maximum number of binding sites) to a value shared
between all inhibitors (Figure 3). The half maximal inhibitory
concentration (IC50) was calculated using a global nonlinear
regression with the equation inhibitor concentration vs. response
constraining the top and bottom parameters to equal 100 and
0 respectively (Figures 4, 5, 8). The significance of inhibitory
differences was analyzed using one-way ANOVA with Tukey’s
corrections for multiple comparisons on the best-fit IC50 values
from data sets with an acceptable goodness-of-fit (adjusted
R-squared > 0.8). Significance of the binding of rMBL and
MBL-dependent C4 deposition on the surface of HK-2 cells was
assessed using a two-tailed t-test, while inhibition was analyzed
using multiple unpaired t-tests with the Holm-Sidak correction
for multiple comparisons. Data are represented as mean ± SEM
of three independent experiments.
RESULTS
Production and Purification of Chimeric
Proteins
We designed two differently-oriented chimeric inhibitors: MAP-
1:C4BP1−5, with the first five CCP domains of the α-chain
of C4BP (alias C4BP1−5) located in the C-terminus of MAP-
1; and C4BP1−5:MAP-1, where C4BP1−5 was placed in the
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N-terminus of MAP-1 via a flexible glycine-serine linker. A
control protein, C4BP1−5 without MAP-1, was designed with
a terminal hexa His-tag (Figure 1A). All three constructs were
cloned into a pcDNA5/FRT plasmid and transfected into Flp-In
CHO cells. MAP-1-containing chimeric proteins were purified
by antibody affinity chromatography and C4BP1-5 was purified
via immobilized metal ion affinity chromatography on a HisTrap
excel column. Under reducing conditions, the chimeric proteins
FIGURE 1 | Recombinant constructs and purified proteins. (A) Diagram of the domain distribution of MAP-1, C4BP α-chain and the recombinant proteins. (B) Instant
blue stain of purified MAP-1:C4BP1−5, C4BP1−5:MAP-1, and C4BP1−5via affinity chromatography. (C) The identity of the protein bands was confirmed by Western
blotting using anti-MAP-1 mAb and rMAP-1 as positive control.
FIGURE 2 | Gel filtration chromatography of chimeric proteins. (A) Gel filtration profile of MAP-1:C4BP1−5 (M:C) and C4BP1−5:MAP-1 (C:M) under physiological
calcium conditions or 10mM EDTA. The identity of the gel filtration profiles was confirmed by analyzing the elution fractions of M:C (B) or C:M (C) by sandwich ELISA
using anti-C4BP as capture antibody and anti-MASP-1/-3/MAP-1 as detection. Relative abundance of the chimeric proteins in the elution fractions following gel
filtration under calcium conditions or EDTA is expressed as OD. mAU, milli absorption units.
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FIGURE 3 | MAP-1:C4BP1−5 (M:C), C4BP1−5:MAP-1 (C:M) and MAP-1
binding to MBL (A) and CL-11 (B). rMBL and rCL-11 were immobilized onto
mannan-coated plates. Recombinant proteins were applied in a two-fold
dilution in the presence of calcium or EDTA. Binding was determined using an
anti-MAP-1 mAb. Connecting lines display nonlinear fitting using the equation
specific binding with hill slope. Results are representative of three independent
experiments and error bars represent minimum and maximum values of
triplicate measurements.
migrated as a single band with an apparent molecular weight
of ∼80 kDa, equivalent to the sum of rMAP-1 and rC4BP1−5
molecular weights (i.e., ∼44 kDa and ∼37 kDa respectively;
Figure 1B). The identity of the protein bands was confirmed by
Western blotting (Figure 1C).
MAP-1:C4BP1−5 and C4BP1−5:MAP-1 Form
Dimers and Associate With the Collectins
of the LP in the Presence of Calcium
The MASPs are known to form head-to-tail dimers via the
interaction of the CUB1 and EGF domains and to associate
with the recognition molecules of the LP in a Ca2+-dependent
manner (18, 47, 48). To study the effect of calcium in the
dimerization of our recombinant inhibitors, we performed gel
filtration with and without EDTA, a Ca2+-chelating agent. Both
chimeric proteins eluted in a single overlapping peak in fractions
6–8 under physiological calcium concentrations. In the presence
of EDTA, the previous peak was drastically reduced and a new
one appeared in fractions 7–9 indicating that both are capable of
assembling into dimers stabilized by Ca2+ (Figure 2).
Both chimeric proteins and MAP-1 were able to bind to
rMBL and rCL-11 in a dose-dependent manner with equivalent
dose-response curves in the presence of Ca2+ (Figure 3). On
rMBL, MAP-1:C4BP1−5 and C4BP1−5:MAP-1 exhibited a similar
FIGURE 4 | Chimeric and rMAP-1 complement inhibition after pre-incubation
on rMBL/mannan. Serial dilutions of MAP-1:C4BP1−5 (M:C),
C4BP1−5:MAP-1 (C:M), and rMAP-1 were allowed to form complexes with
mannan-bound rMBL prior to addition of MBL-defect serum as a source of
complement. Detection of C4 (A), C3 (B), and TCC (C) deposition was
quantified using anti-C4, anti-C3, and anti-TCC mouse mAbs. Connecting
lines are four parameters nonlinear fitting using the equation inhibitor
concentration vs. slope. Data are reported as
[(ODinhibitor-ODbackground)/(ODnoinhibitor-ODbackground)]100. Error bars
represent the SEM of three independent experiments, and the dashed line the
50% inhibition level. *P < 0.05; ***P < 0.001; ****P < 0.0001.
Kd of 0.35 and 0.56 nM respectively, slightly lower affinity
than rMAP-1 at the given conditions (0.14 nM; Figure 3A). The
same tendency, albeit with weaker interactions, was observed
with rCL-11 (Figure 3B): rMAP-1 displayed the lowest Kd
(1.65 nM), followed by MAP-1:C4BP1−5 (1.97 nM) and lastly
C4BP1−5:MAP-1 (5.49 nM). As expected, no binding could be
detected when the proteins were incubated in the presence of
EDTA.
Inhibition of LP Activation With MBL Defect
Serum and NHS
To study the effect of the chimeric constructs on LP-mediated
complement activation we used mannan-bound rMBL as
the activating PRM. MAP-1:C4BP1−5 and C4BP1−5:MAP-1
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FIGURE 5 | Chimeric and rMAP-1 complement inhibition after co-incubation
with NHS. Serial dilutions of MAP-1:C4BP1−5 (M:C), C4BP1−5:MAP-1 (C:M),
and rMAP-1 were co-incubated with 2% NHS in non-adsorbent titration plates
for 30min prior to addition to mannan-bound rMBL. Detection of deposition of
C4 (A), C3 (B), and TCC (C) was determined as described before. Connecting
lines are four parameters nonlinear fitting using the equation inhibitor
concentration vs. slope. Dashed line Data are reported as [(ODinhibitor –
ODbackground)/(ODnoinhibitor – ODbackground)]100. Error bars represent the
SEM of three independent experiments, and the dashed line the 50% inhibition
level. *P < 0.05; ***P < 0.001.
exhibited a strong dose-dependent inhibition on C4, C3, and
TCC level when they were allowed to form complexes with
rMBL prior to the addition of 2% MBL defect serum as
complement source (Figure 4). rMAP-1 was the most effective at
the C4 level: IC50 MAP-1 (0.14 nM) vs. IC50 MAP-1:C4BP1−5
(0.45 nM), non-significant; IC50 MAP-1 (0.14 nM) vs. IC50
C4BP1−5:MAP-1 (1.2 nM), P < 0.0001. Nonetheless, MAP-
1:C4BP1−5 outperformed the rest when measuring C3 (IC50
MAP-1:C4BP1−5 = 0.36 nM vs. 7.72 nM C4BP1−5:MAP-1, P <
0.05, and 3.35 nM MAP-1, non-significant) and TCC deposition
(IC50MAP-1:C4BP1−5= 0.17 nM vs. 0.92 nMC4BP1−5:MAP-1,
P < 0.0001, and 0.46 nMMAP-1, P < 0.05).
Next, we tested the inhibitors by directly incubating them
with 2% NHS in non-adsorbent titration plates before applying
the inhibitor/serum mix to mannan (Figure 5). Under these
conditions, both chimeric inhibitors demonstrated higher
inhibition than rMAP-1 alone in the later steps of the
complement cascade (i.e., C3 and TCC formation). MAP-
1:C4BP1−5 exhibited a more pronounced inhibition of C4 (non-
significant tendency), C3 (P < 0.05), and TCC deposition (P <
0.001). The other construct appeared to be less active but still
outperformed rMAP-1 at the C3 (non-significant trend) and TCC
levels (P < 0.05). No complement deposition was observed when
MBL defect serum was incubated without rMBL (Figure 4) or
with rMBL but no mannan (Figure 5).
C4BP Cofactor Activity in FI-Mediated
Cleavage of Soluble C4b/C3b
It has previously been reported that C4BP can act as a cofactor in
the fI-mediated proteolytic inactivation of C3b and C4b (29, 31,
49). Hence we examined whether our chimeric proteins retained
the fI cofactor activity of native C4BP.
When C4b was incubated with fI in combination with native
full length C4BP or one of the two chimeric proteins, the α-chain
of C4b was cleaved and a band corresponding to the smaller
cleavage product C4d appeared (Figure 6A). As expected no
full cofactor activity was observed for MAP-1 but the cleavage
product iC4b was observed when MAP-1 was in combination
with FI and C4b. Similarly, a low level proteolysis of C3b into
iC3b could be observed in the presence of fI and MAP-1. Both
are probably artifacts from the elevated fI concentrations used
in the assays. No C4b proteolysis was apparent in the absence
of cofactors or fI, with the notable exception of purified native
C4BP. When C4b was incubated with C4BP alone a cleavage of
the α-chain and generation of the iC4b was observed, hinting at
a possible contamination of the purified C4BP. We performed a
new immunoblotting with C4BP alone and in combination with
fI or C4b. The iC4b band was visible in all wells, suggesting that
iC4b had been co-purified with C4BP (data not shown).
A cleavage of the C3b α-chain band was observed together
with the appearance of a band corresponding to iC3b when C3b
was subjected to fI in combination with C4BP or one of the
two chimeric proteins (Figure 6B). Full cleavage of C3b to C3dg
could only be archived when fH was applied in combination with
C3b and fI. As expected no cofactor activity was observed for
MAP-1.
Reduction of MBL-Dependent C4
Deposition in Kidney Proximal Tubular
Epithelial Cells
The complement system, and in particular MBL, has been
documented as one of the key mediators of kidney injury
following renal ischemia (50–53). Proximal tubular epithelial
cells (PTECs), responsible for many regulatory and endocrine
functions, are especially vulnerable to complement-mediated
tissue damage (51). After demonstrating the efficacy of our
chimeric inhibitors in the previous ELISA-based assays, we
tested whether we could quench complement activation on
PTECs. A dose-dependent MBL binding was observed when
human PTECs were incubated with increasing concentrations
of rMBL (Figure 7A). Binding could be neutralized with the
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FIGURE 6 | Cofactor activity in factor I-mediated C4b and C3b cleavage. Purified C3b or C4b was incubated with fI and different cofactors for 2 h at 37◦C. The
reactions were stopped with LDS buffer and subjected to western blotting under reducing conditions using C4d and C3d antibodies. (A) Incubation of C4b with fI in
the presence of C4BP, fH or C4BP-containing chimeric proteins resulted in the generation of a band corresponding to the inactive degradation products iC4b and
C4d. (B) Incubation of C3b with fI in the presence of C4BP, fH or C4BP-containing chimeric proteins results in the generation of the 68 kDa degradation fragment.
M:C, MAP-1:C4BP1−5; C:M, C4BP1−5:MAP-1. The blots are representative of three independent experiments.
addition of EDTA in the sample buffer, suggesting a classical
c-type lectin interaction. Addition of 10% MBL defect serum
to MBL-bound PTECs led to C4 deposition on the cell surface
(Figure 7B) that was significantly reduced when rMAP-1 or the
MAP-1-containing chimeras were incubated in a concentration
of 200 nM with serum prior to addition to the MBL-bound
cells as compared to the no inhibitor control (Figure 7C).
Equimolar concentrations of rC4BP1−5 alone showed no
significant reduction of C4 deposition.
Total Complement Screen
We further assessed the ability of the chimeric inhibitors to
regulate all three complement pathways using the commercial
total complement screen assay Wielisa (45) (Figure 8). In
agreement with the above results MAP-1:C4BP1−5 was the
most effective construct, significantly outperforming all other
inhibitors in the LP (Figure 8A) and CP (Figure 8B) activation
assays, while C4BP1−5:MAP-1 demonstrated a more modest
activity. The combination of rC4BP1−5 and rMAP-1 displayed
an inhibitory potential comparable to C4BP1−5:MAP-1, and 5
to 10 times lower than MAP-1:C4BP1−5. In the AP however
(Figure 8C), MAP-1:C4BP1−5 had only a minor effect, with an
IC50 value comparable to rC4BP1−5 (alone or in combination
with rMAP-1). Inhibitors whose dose-response curves had a
fitting with an adjusted R-square value < 0.8 were excluded for
the analysis—such as rMAP-1 (Figures 8A,B) and all inhibitors
besides MAP-1:C4BP1−5 in the AP activation assay (Figure 8C).
DISCUSSION
The unique position of the complement system as an early
danger sensor and conductor of downstream humoral and
cellular responses makes complement modulation an attractive
pharmacological target (36, 54). Rational engineering of existing
complement regulators and novel recombinant inhibitors
targeting complement on different levels has proven to be a
successful strategy, such as mini-fH (41) and chimeric regulators
composed of the N-terminal domains of fH merged with CRIg
(55) or soluble CR2 (40). Complement factor H is the main
soluble regulator of the AP and with CRIg being a C3 regulator
Frontiers in Immunology | www.frontiersin.org 8 August 2018 | Volume 9 | Article 1945
Hertz et al. Dual Targeting of Complement Activation
FIGURE 7 | Inhibition of complement deposition on tubular proximal kidney
epithelial cells. (A) HK-2 cells were incubated with increasing concentrations of
rMBL at 4◦C and bound MBL was determined using an anti-MBL mAb. (B)
Binding of MBL results in the deposition of C4. HK-2 cells were incubated with
rMBL followed by 10% MBL defect serum for 1 h at 4◦C. Bound C4 was
determined using an anti-C4c pAb. (C) rMBL-mediated C4 deposition after
MAP-1:C4BP1−5 (M:C), C4BP1−5:MAP-1 (C:M), rMAP-1 or full length C4BP
co-incubation with 10% MBL defect serum. Inhibition is reported as the ratio
of the MFI of the inhibitor to the MFI of the bank (MFIinh:MFIblank ). Significance
was tested for each concentration of the inhibitors compared to the blank.
Data are reported as the mean ± SEM of three independent experiments.
and CR2 an inhibitor of C3 deposition all these molecules
affect exclusively the alternative amplification loop. However,
increasing understanding of the involvement of complement in
highly diverse clinical conditions suggests a different approach
with complement-targeted drugs interfering at various stages
of the cascade (35). Our group has previously tested this
strategy by combining full length MAP-1 with the first five
CCPs of fH, generating a chimeric protein with the potential
to target initial recognition and at the same time down-
regulate AP amplification (37). We wanted to investigate this
approach further and designed two differently-oriented proteins
FIGURE 8 | Wielisa total complement screen. Serial dilutions of
MAP-1:C4BP1−5 (M:C), C4BP1−5:MAP-1 (C:M), rMAP-1, rC4BP1−5, and
rMAP-1 and rC4BP1−5 together (M+C) were incubated with NHS and
subsequently the protein/serum mix was applied to pre-coated Wielisa plates.
Complement activation was quantified using an anti-TCC mAb. (A) Lectin
pathway activation on mannan-coated plates. (B) Classical pathway activation
on IgM-coated plates. (C) Alternative activation on LPS-coated plates.
Connecting lines are nonlinear fitting using the equation inhibitor concentration
vs. slope. Values represent OD readings normalized to the OD of the wells
without inhibitor times 100. Significance was tested for best-fit IC50 values of
data sets with an adjusted R-squared > 0.8. Error bars represent the SEM of
three independent experiments, and the dashed line the 50% inhibition level.
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
by genetic engineering; MAP-1:C4BP1−5, with the sequence
of human C4BP1−5 fused directly downstream of full length
human MAP-1, and C4BP1−5:MAP-1, where C4BP1−5 was
located in the N-terminus and connected to MAP-1 via a
flexible glycine-serine linker. In theory, combining two existing
complement inhibitors could result in a synergistic effect, giving
rise to unique complement-regulatory and anti-inflammatory
properties. Furthermore, we hypothesize that the ability of
targeting both CP and LP activation may be especially beneficial
in multifactorial pathologies where both pathways are involved
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in driving tissue damage, such as ischemia/reperfusion injuries
(56).
MAP-1 forms head-to-tail homodimers (18) stabilized
by calcium, that upon complex formation with collectins
and ficolins downregulate LP activation (18, 57, 58). MAP-
1:C4BP1−5, C4BP1−5:MAP-1, and rMAP-1 displayed comparable
Kd values to rMBL (0.35, 0.56, 0.14 nM respectively) and rCL-11
(1.97, 5.49, and 1.65 nM respectively) in a solid-phase ELISA
setup. Hill slopes values above 1 indicate a multivalent binding
to MBL. The lower hill slope values observed with rCL-11 may
be a consequence of its limited oligomerization and reflect the
reduced number of collagen-stalks available for complexation
with the inhibitors. Addition of the calcium-chelating agent
EDTA completely inhibited binding. This clearly indicates that
the interaction of the chimeras with the PRMs is mediated
through their MAP-1 part in a calcium-dependent manner. No
binding was observed with rC4BP1−5 (data not shown).
To investigate the dimerization in detail both chimeras were
subjected to SEC in the presence of physiological calcium
concentrations or EDTA. We found that both constructs eluted
as a single peak in the presence of calcium, whereas when exposed
to EDTA-containing buffers the chimeras were separated into
monomers leading to a shift in their spectrophotogram profiles
toward a lower estimated molecular size. The identity of the
peaks was confirmed using a specific ELISA capturing C4BP and
detecting MAP-1. These results demonstrate that the constructs
maintain the calcium-dependent dimerization of native MAP-1
that is critical for its role as an LP inhibitor.
Our group and others have previously demonstrated that
rMAP-1 alone and as part of chimeric constructs inhibits LP
activation in vitro (18, 20, 21, 37, 39). Here we tested the
ability of the chimeric proteins to regulate LP activation in
different functional ELISAs. First we incubated the chimeric
proteins, rMAP-1, and C4BP1−5 with MBL bound to mannan-
coated plates, and subsequently added 2% MBL defect serum
as complement source. While rMAP-1 alone seemed more
effective at inhibiting C4 deposition, MAP-1: C4BP1−5
clearly outperformed rMAP-1 on the C3 and TCC levels.
C4BP1−5:MAP-1 was the least effective regulator of the three.
If C4 regulation is solely dependent on MAP-1, then differences
on C4 inhibition could be explained by their different binding
affinities toward MBL. In a more physiologically-relevant
ELISA setup the proteins were co-incubated with 2% NHS,
thus allowing direct competition between the inhibitors and
intrinsic MASPs for binding to MBL. Again, incubation with
MAP-1:C4BP1−5 caused a significant inhibition resulting in
the almost complete absence of C3, and TCC deposition.
While C4BP1−5:MAP-1 failed to provide the same inhibition
as MAP-1:C4BP1−5, it was still more effective than rMAP-1
alone. The difference in inhibition levels of rMAP-1 observed
in the two experimental setups is in agreement with other
studies (18, 37) and could be attributed to competition with
the MASPs on MBL binding. This phenomenon supports our
explanation that rMAP-1 occupies MASPs-binding sites at the
MBL molecules when pre-incubated (20), that would result
in either a lower concentration of catalytically-active MASPs
or/and a decreased intercomplex activation by spacing out
MBL/MASPs complexes (59). When added simultaneously
with serum, rMAP-1 may not be capable of displacing already
formed MBL/MASPs complexes (at least under our experimental
conditions).
It has been reported that the domains CCP1-4 of the α-chain
are critical for the fI cofactor activity of C4BP in the fI-mediated
C4b (28–30) and C3b proteolytic inactivation (31). Thereby we
expected that the chimeric proteins will manifest intact fI cofactor
activity. We showed that C4BP1−5-containing constructs were
as efficient as full length native C4BP in a fluid phase C3b/C4b
degradation assay. Moreover it appears that C4BP is a more
effective cofactor in the cleavage of C4b compared to C3b in
agreement with a previous study (49).
We next looked for a pathological condition where
complement injury was triggered by an initial recognition
by the LP. MBL has been documented to be directly involved
in kidney damage following renal ischemia (53). We used
immortalized human PTECs to test whether we could quench
the exacerbated complement activation observed on the tubular
epithelium, known to be especially vulnerable to complement
attack after reperfusion (51). In agreement with the literature
rMBL was capable of binding to the cell surface in a calcium-
dependent manner, suggesting a traditional c-type lectin
interaction (60). Binding to PTECs led to the deposition of C4
activation fragments. As seen on ELISA, the chimeras and rMAP-
1 presented comparable regulatory effects (even when using a
five times lower serum dilution than in ELISA). This to a degree
limited inhibition can be expected assuming that trace amounts
of PRM/MASPs complexes are sufficient to cause detectable C4
deposition, which in turn is mainly mediated by the MAP-1 part
while the effect on the late cascade (i.e., C3 and TCC) depends
on the combination of MAP-1 and C4BP. No C3 or TCC
deposition was observed (see Supplementary Figure 2). The
assay was performed at 4◦C, that while it allowed the cleavage
and deposition of C4, it did not result in the assembly of the
downstream convertases [62]. Incubation of MBL-bound cells at
37◦C led to the disappearance of C4 and MBL surface stain (data
not shown). It has been reported that binding of MBL to PTEC
causes its internalization followed by complement-independent
cell death (60). Thus, this assay may have some inherited
limitations to study downstream complement deposition, but
is suitable to study the initial inhibiting effect of PRM binding
inhibitors.
Finally, we tested the regulatory effect of the chimeric proteins
in all three complement pathways using Wielisa, a platform for
standardized complement activity measurements. In agreement
with our previous results, MAP-1:C4BP1−5 demonstrated a
strong dose-dependent inhibition of TCC deposition in the
LP (IC50 = 13.15 nM). Remarkably, it was also an efficient
CP inhibitor (IC50 = 4.83 nM), outperforming rMAP-1 and
C4BP1−5 alone or in combination. C4BP1−5:MAP-1 inhibited the
LP and CP to a lesser extent than MAP-1:C4BP1−5, equivalent to
rMAP-1 and rC4BP1−5 added at the same time. The equivalent
regulatory effects of the chimeras in the LP and CP, together
with the moderate activity of rMAP-1 in the LP, suggests that
the observed LP-downregulation is mainly driven by the C4BP
part, reflecting a limitation of the assay as a model for LP-
mediated activation. Thus, in a physiological setting where both
functional domains of the chimeras would be involved, we may
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observe a more pronounced inhibition [as shown for rMAP-
1 (21)]. It should be noted that even though MAP-1 only
associates with the PRMs of the LP and not the CP, MAP-1-
containing chimeras were more effective than C4BP1−5 alone
in both CP and LP. This implies that the combination of two
regulators within a single molecule—in the right configuration—
enables the enhanced functionality of the constructs, and not
just displays the function of “free” MAP-1 or C4BP. In the AP
activation assay MAP-1:C4BP1−5 showed only a minor effect—
around 100 to 400-fold lower than in the LP and CP—that was
directly comparable to rC4BP1−5 (alone or in combination with
rMAP-1), suggesting that AP activity is solely mediated by the
C4BP part. It is important to highlight that the above-described
experiments were performed using diluted serum as a source
of complement. Experiments using animal models would be
necessary to demonstrate that the chimeric proteins are effective
complement inhibitors under physiological conditions.
The mechanism behind the observed differences in inhibitory
properties between MAP-1:C4BP1−5 and C4BP1−5:MAP-
1 remain unclear, although it could be explained by their
quaternary structure. Dimerization of C4BP1−5:MAP-1 could
result in MAP-1 bending away from C4BP1−5 via the flexible
region in the CUB2/EGF region and the artificial linker between
C4BP1−5 and MAP-1. This contorted folding could give rise to
a dimer with impaired ability to reach C4b/C3b and possibly
also hindering the complex formation with MBL. On the other
hand, MAP-1:C4BP1−5 may fold into an elongated dimer with
C4BP1−5 pointing outwards from a MAP-1 dimer core bound
to the collagen-like stalks of the PRMs similar to how the
serine domain in the MASPs is assumed to protrude when
bound to MBL. This conformation would enable both C4BP1−5
monomers to interact with deposited C4b/C3b in the vicinity
of the PRM binding site. We propose that the MAP-1 fragment
may “dock” the chimeric inhibitor to the PRMs directing the
multifunctional soluble inhibitor C4BP to the activating surface,
thus increasing the efficacy. While data presented by our group
in the present and past reports (37) provide a solid support
for our hypothesis, conclusive evidence will require precise
structural determination techniques, such as circular dichroism,
multi-angle light scattering, small-angle x-ray scattering, or x-ray
crystallography.
In conclusion, we have successfully developed a novel
complement inhibitor that harnesses the multifaceted
functionality of the fluid phase CP and LP regulator C4BP,
and directs it to danger foci by the specific association to
PRMs mediated by MAP-1. The combination of MAP-1
fused to C4BP1−5 presents unique complement regulatory
properties in vitro and represents a potential novel therapeutic
approach by targeting both upstream and central complement
activation.
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Supplementary Figure 1 | Gating strategy. HK-2 cells were defined as a uniform
population on the forward scatter (FS INT) vs. side scatter (SS INT) plot, and single
cells were selected gating on the forward scatter area or integral values (FS INT)
vs. forward scatter height or peak (FS PEAK).
Supplementary Figure 2 | MBL-dependent complement deposition on HK-2
cells. Cells were incubated with rMBL for 30min at 4◦C prior to addition of 10%
MBL defect serum for 1 h at 4◦C. Deposition of C4 (A), C3 (B), and TCC (C). Cells
incubated with no MBL, or with MBL but no serum were used as controls. X-Med,
median fluorescence intensity.
REFERENCES
1. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement
system part I - molecular mechanisms of activation and regulation. Front
Immunol. (2015) 6:1–30. doi: 10.3389/fimmu.2015.00262
2. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system
for immune surveillance and homeostasis. Nat Immunol. (2010) 11:785–97.
doi: 10.1038/ni.1923
3. Kersse K, Bertrand MJM, Lamkanfi M, Vandenabeele P. NOD-
like receptors and the innate immune system: coping with danger,
damage and death. Cytokine Growth Factor Rev. (2011) 22:257–76.
doi: 10.1016/j.cytogfr.2011.09.003
4. Doyle SL, O’Neill LAJ. Toll-like receptors: from the discovery of NFkB to
new insights into transcriptional regulations in innate immunity. Biochem
Pharmacol. (2006) 72:1102–13. doi: 10.1016/j.bcp.2006.07.010
5. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol.
(2010) 125:S3–23. doi: 10.1016/j.jaci.2009.12.980
6. Noris M, Remuzzi G. Overview of complement activation and regulation.
Semin Nephrol. (2013) 33:479–92. doi: 10.1016/j.semnephrol.2013.08.001
7. Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH. Paths
reunited: initiation of the classical and lectin pathways of complement
activation. Immunobiology (2010) 215:1–11. doi: 10.1016/j.imbio.2009.
08.006
8. Kishorea U, Rohit Ghaib, Trevor J. Greenhoughc, Shrivec AK, Bonifatid
DM et al. Structural and functional anatomy of the globular domain
of complement protein C1q. Immunol Lett. (2004) 100:113–28.
doi: 10.1016/j.imlet.2004.06.015
9. Gaboriaud C, Frachet P, Thielens NM, Arlaud GJ. The human C1q globular
domain: Structure and recognition of non-immune self ligands. Front
Immunol. (2012) 2:1–8. doi: 10.3389/fimmu.2011.00092
Frontiers in Immunology | www.frontiersin.org 11 August 2018 | Volume 9 | Article 1945
Hertz et al. Dual Targeting of Complement Activation
10. Garred P, Genster N, Pilely K, Bayarri-Olmos R, Rosbjerg A, Ma YJ, et al.
A journey through the lectin pathway of complement-MBL and beyond.
Immunol Rev. (2016) 274:74–97. doi: 10.1111/imr.12468
11. Bexborn F, Andersson PO, Chen H, Nilsson B, Ekdahl KN. The tick-
over theory revisited: Formation and regulation of the soluble alternative
complement C3 convertase (C3(H2O)Bb). Mol Immunol. (2008) 45:2370–9.
doi: 10.1016/j.molimm.2007.11.003
12. Harboe M, Mollnes TE. The alternative complement pathway revisited. J Cell
Mol Med. (2008) 12:1074–84. doi: 10.1111/j.1582-4934.2008.00350.x
13. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate
complement activation by binding specific target surfaces and providing a
platform for de novo convertase assembly. J Immunol. (2007) 179:2600–8.
doi: 10.4049/jimmunol.179.4.2600
14. Harboe M, Johnson C, Nymo S, Ekholt K, Schjalm C, Lindstad JK,
et al. Properdin binding to complement activating surfaces depends on
initial C3b deposition. Proc Natl Acad Sci USA. (2017) 114:E534–9.
doi: 10.1073/pnas.1612385114
15. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev
Immunol. (2009) 9:729–40. doi: 10.1038/nri2620
16. Roy D, Steyer GJ, Gargesha M, Stone ME, Wilson L, Davis AE, et al.
Biological activities Of C1 inhibitor. Mol Immunol. (2008) 45:4057–63.
doi: 10.1016/j.molimm.2008.06.028
17. Keizer MP, Wouters D, Schlapbach LJ, Kuijpers TW. Restoration of MBL-
deficiency: redefining the safety, efficacy and viability of MBL-substitution
therapy.Mol Immunol. (2014) 61:174–84. doi: 10.1016/j.molimm.2014.06.005
18. Skjoedt M, Roversi P, Hummelshøj T, Palarasah Y, Rosbjerg A, Johnson S,
et al. Crystal structure and functional characterization of the complement
regulator mannose-binding lectin (MBL). J Biol Chem. (2012) 287:32913–21.
doi: 10.1074/jbc.M112.386680
19. Skjoedt MO, Hummelshoj T, Palarasah Y, Hein E, Munthe-Fog L,
Koch C, et al. Serum concentration and interaction properties of
MBL/ficolin associated protein-1. Immunobiology. (2011) 216:625–32.
doi: 10.1016/j.imbio.2010.09.011
20. Degn SE, Hansen AG, Steffensen R, Jacobsen C, Jensenius JC, Thiel S, et al.
MAp44, a human protein associated with pattern recognition molecules of
the complement system and regulating the lectin pathway of complement
activation. J Immunol. (2009) 183:7371–8. doi: 10.4049/jimmunol.0902388
21. Pavlov VI, Skjoedt MO, Tan YS, Rosbjerg A, Garred P, Stahl GL.
Endogenous and natural complement inhibitor attenuates myocardial
injury and arterial thrombogenesis. Circulation (2012) 126:2227–35.
doi: 10.1161/CIRCULATIONAHA.112.123968
22. Banda NK, Mehta G, Kjaer TR, Takahashi M, Schaack J, Morrison
TE, et al. Essential role for the lectin pathway in collagen antibody-
induced arthritis revealed through use of adenovirus programming
complement inhibitor MAp44 expression. J Immunol. (2014) 193:2455–68.
doi: 10.4049/jimmunol.1400752
23. OshiumiH, Shida K, Goitsuka R, Kimura Y, Katoh J, Ohba S, et al. Regulator of
complement activation (RCA) locus in chicken: identification of chicken RCA
gene cluster and functional RCA proteins. J Immunol. (2005) 175:1724–34.
doi: 10.4049/jimmunol.175.3.1724
24. Dahlbäck B, Smith CA, Müller-Eberhard HJ. Visualization of human C4b-
binding protein and its complexes with vitamin K-dependent protein S and
complement protein C4b. Proc Natl Acad Sci USA. (1983) 80:3461–5.
25. Hillarp A, Dahlbäck B. Cloning of cDNA coding for the beta chain of human
complement component C4b-binding protein: sequence homology with the
alpha chain. Proc Natl Acad Sci USA. (1990) 87:1183–7.
26. Gigli I, Fujita T, Nussenzweig V, Gigli, I, Fujita, T, Nussenzweig V.Modulation
of the classical pathway C3 convertase by plasma proteins C4 binding protein
and C3b inactivator. Proc Natl Acad Sci USA. (1979) 76(3 Pt 1):6596–600.
doi: 10.1073/pnas.76.12.6596
27. Suankratay C, Mold C, Zhang Y, Lint TF, Gewurz H. Mechanism of
complement-dependent haemolysis via the lectin pathway: role of the
complement regulatory proteins. Clin Exp Immunol. (1999) 117:442–8.
doi: 10.1046/j.1365-2249.1999.00998.x
28. Fujita T, Gigli I, Nussenzweig V. Human C4-binding protein. II. Role in
proteolysis of C4b by C3b-inactivator. J Exp Med. (1978) 148:1044–51.
doi: 10.1084/jem.148.4.1044
29. Scharfstein BYJ, Ferreira A, Gigli I. Human C4-binding protein. i isolation
and characterization. J Exp Med. (1978) 148:207–22.
30. Nagasawa S, Ichihara C, Stroud RM. Cleavage of C4b by C3b inactivator:
production of a nicked form of C4b, C4b’, as an intermediate cleavage product
of C4b by C3b inactivator. J Immunol. (1980) 125:578–82.
31. Blom AM, Kask L, Dahlbäck B. CCP1 – 4 of the C4b-binding protein alpha-
chain are required for factor I mediated cleavage of complement factor C3b.
Mol Immunol. (2003) 39:547–56.
32. Ermert D, Blom AM. C4b-binding protein: the good, the bad and the
deadly. Novel functions of an old friend. Immunol Lett. (2016) 169:82–92.
doi: 10.1016/j.imlet.2015.11.014
33. Blom AM, Nandakumar KS, Holmdahl R. C4b-binding protein (C4BP)
inhibits development of experimental arthritis in mice. Ann Rheum Dis.
(2009) 68:136–42. doi: 10.1136/ard.2007.085753
34. US Food and Drug Administration. FDA Approves First-of-Its-Kind Drug to
Treat Rare Blood Disorder [Internet]. Rockville, MD, USA; Available online at:
http://www.fda.gov/bbs/topics/NEWS/2007/NEW01589.html
35. Ricklin D, Lambris JD. New milestones ahead in complement-targeted
therapy. Semin Immunol. (2016) 28:208–22. doi: 10.1016/j.smim.2016.06.001
36. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders:
therapeutic interventions. J Immunol Ref J Immunol. (2013) 190:3839–47.
doi: 10.4049/jimmunol.1203200
37. Nordmaj MA, Munthe-Fog L, Hein E, Skjoedt MO, Garred P. Genetically
engineered fusion ofMAP-1 and factor H domains 1-5 generates a potent dual
upstream inhibitor of both the lectin and alternative complement pathways.
FASEB J. (2015) 29:4945–55. doi: 10.1096/fj.15-277103
38. Jung S-K, McDonald K. Visual gene developer: a fully programmable
bioinformatics software for synthetic gene optimization. BMC Bioinformatics
(2011) 12:340. doi: 10.1186/1471-2105-12-340
39. Skjoedt MO, Hummelshoj T, Palarasah Y, Honore C, Koch C, Skjodt K, et al.
A novel mannose-binding lectin/ficolin-associated protein is highly expressed
in heart and skeletal muscle tissues and inhibits complement activation. J Biol
Chem. (2010) 285:8234–43. doi: 10.1074/jbc.M109.065805
40. Hebecker M, Alba-Dominguez M, Roumenina LT, Reuter S, Hyvarinen
S, Dragon-Durey M-A, et al. An engineered construct combining
complement regulatory and surface-recognition domains represents
a minimal-size functional factor H. J Immunol. (2013) 191:912–21.
doi: 10.4049/jimmunol.1300269
41. Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, Ricklin D, et al. Rational
engineering of a minimized immune inhibitor with unique triple-targeting
properties. J Immunol. (2013) 190:5712–21. doi: 10.4049/jimmunol.1203548
42. Skjoedt MO, Palarasah Y, Munthe-Fog L, Jie Ma Y, Weiss G, Skjodt K, et al.
MBL-associated serine protease-3 circulates in high serum concentrations
predominantly in complex with Ficolin-3 and regulates Ficolin-3
mediated complement activation. Immunobiology (2010) 215:921–31.
doi: 10.1016/j.imbio.2009.10.006
43. Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding
lectin deficiency—revisited. Mol Immunol. (2003) 40:73–84.
doi: 10.1016/S0161-5890(03)00104-4
44. Garred P, Mollnes TE, Lea T, Fischer E. Characterization of a monoclonal
antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on
C3b, iC3b, and C3c. Scand J Immunol. (1988) 27:319–27.
45. Seelen MA, Roos A, Wieslander J, Mollnes TE, Sjöholm AG, Wurzner R,
et al. Functional analysis of the classical, alternative, and MBL pathways of
the complement system: standardization and validation of a simple ELISA. J
Immunol Methods (2005) 296:187–98. doi: 10.1016/j.jim.2004.11.016
46. Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B.
HK-2: an immortalized proximal tubule epithelial cell line from normal adult
human kidney. Kidney Int. (1994) 45:48–57. doi: 10.1038/ki.1994.6
47. Teillet F, Gaboriaud C, Lacroix M, Martin L, Arlaud GJ, Thielens NM.
Crystal structure of the CUB1-EGF-CUB2 domain of human MASP-1/3 and
identification of its interaction sites with mannan-binding lectin and ficolins.
J Biol Chem. (2008) 283:25715–24. doi: 10.1074/jbc.M803551200
48. Thielens NM, Cseh S, Thiel S, Vorup-Jensen T, Rossi V, Jensenius JC, et al.
Interaction properties of human mannan-binding lectin (MBL)-associated
serine proteases-1 and−2, MBL-associated protein 19, and MBL. J Immunol.
(2001) 166:5068–77. doi: 10.4049/jimmunol.166.8.5068
Frontiers in Immunology | www.frontiersin.org 12 August 2018 | Volume 9 | Article 1945
Hertz et al. Dual Targeting of Complement Activation
49. Seya T, Nakamura K, Masaki T, Ichihara-Itoh C, Matsumoto M, Nagasawa
S. Human factor H and C4b-binding protein serve as factor I-cofactors both
encompassing inactivation of C3b and C4b.Mol Immunol. (1995) 32:355–60.
doi: 10.1016/0161-5890(94)00157-V
50. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM.
Lack of a functional alternative complement pathway ameliorates
ischemic acute renal failure in mice. J Immunol. (2003) 170:1517–23.
doi: 10.4049/jimmunol.170.3.1517
51. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, et al. Predominant
role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. (2000)
105:1363–71. doi: 10.1172/JCI8621
52. Thurman JM. Triggers of inflammation after renal ischemia/reperfusion.
Clin Immunol. (2007) 123:7–13. doi: 10.1016/j.clim.2006.
09.008
53. Moller-Kristensen M, Wang W, Ruseva M, Thiel S, Nielsen S, Takahashi K,
et al. Mannan-binding lectin recognizes structures on ischaemic reperfused
mouse kidneys and is implicated in tissue injury. Scand J Immunol. (2005)
61:426–34. doi: 10.1111/j.1365-3083.2005.01591.x
54. Morgan BP, Harris CL. Complement, a target for therapy in inflammatory
and degenerative diseases. Nat Rev Drug Discov. (2015) 14:857–77.
doi: 10.1038/nrd4657
55. Qiao Q, Teng X, Wang N, Lu R, Guo L, Zhang X, et al. A novel CRIg-targeted
complement inhibitor protects cells from complement damage. FASEB J.
(2014) 28:4986–99. doi: 10.1096/fj.14-258046
56. Chen G, Chen S, Chen X. Role of complement and perspectives
for intervention in transplantation. Immunobiology (2013) 218:817–27.
doi: 10.1016/j.imbio.2012.09.002
57. Wallis R. Interactions between mannose-binding lectin and MASPs during
complement activation by the lectin pathway. Immunobiology (2007) 212:289–
99. doi: 10.1016/j.imbio.2006.11.004
58. Hansen S, Selman L, Palaniyar N, Ziegler K, Brandt J, Kliem A,
et al. Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma
collectin with microbial-binding activity. J Immunol. (2010) 185:6096–104.
doi: 10.4049/jimmunol.1002185
59. Van Der Pol P, Schlagwein N, Van Gijlswijk DJ, Berger SP, Roos A, Bajema
IM, et al. Mannan-binding lectin mediates renal ischemia/reperfusion injury
independent of complement activation. Am J Transplant. (2012) 12:877–87.
doi: 10.1111/j.1600-6143.2011.03887.x
60. Wahrmann M, Exner M, Regele H, Derfler K, Körmöczi GF, Lhotta
K, et al. Flow cytometry based detection of HLA alloantibody mediated
classical complement activation. J Immunol Methods (2003) 275:149–60.
doi: 10.1016/S0022-1759(03)00012-7
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Hertz, Bayarri-Olmos, Kirketerp-Møller, van Putten, Pilely,
Skjoedt and Garred. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 13 August 2018 | Volume 9 | Article 1945
